Home › Funds › PGGM Investments › REGN

PGGM Investments position in REGN

REGENERON PHARMACEUTICALS · Health Care

PGGM Investments reported holding 25,588 shares of REGN (REGENERON PHARMACEUTICALS) in its Q3 2026 13F filing — a position valued at US$19.4M, representing 0.48% of its reported portfolio and ranking #50 among its reported holdings. PGGM Investments has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

Latest position (Q3 2026)25.59K sh
Reported value held$19.40M
Portfolio Weight0.48%
First reportedQ3 2023
Last changeReduce
Updated2026-11-13

Last updated: 2026-11-13 · Source: SEC EDGAR Form 13F-HR

How PGGM Investments's REGN position evolved

PGGM Investments first disclosed a stake in REGN in Q3 2023 at 56,642 shares (US$46.6M). The position peaked in Q1 2026 at 92,584 shares, worth US$71.5M. Across 13 filings, PGGM Investments increased the stake 3 time(s), trimmed it 4 time(s) and left it unchanged 5 time(s). The most recent filing (Q3 2026) shows 25,588 shares valued at US$19.4M — a reduction of -66,996 shares quarter over quarter.. Notable position changes include a 36% trim in Q4 2023 (shares rose 10% over the following quarter), a 160% increase in Q2 2025 (shares rose 8% over the following quarter), a 72% trim in Q3 2026 (shares rose 26% over the following quarter).

Quarter by quarter

QuarterSharesValueChange
Q3 2023 56.64K $46.61M New
Q4 2023 36.03K $31.64M Reduce
Q1 2024 36.03K $34.68M Hold
Q2 2024 32.73K $34.40M Reduce
Q3 2024 26.20K $27.54M Reduce
Q4 2024 32.50K $23.15M Add
Q1 2025 32.50K $20.61M Hold
Q2 2025 84.40K $44.31M Add
Q3 2025 92.58K $52.06M Add
Q4 2025 92.58K $71.46M Hold
Q1 2026 92.58K $71.53M Hold
Q2 2026 92.58K $57.73M Hold
Q3 2026 25.59K $19.40M Reduce

Dots on the line are colored by change type; missing quarters mean no position was reported.

About REGN and 13F data

REGN (REGENERON PHARMACEUTICALS) is a Health Care company. 29 other funds we track also report a position in REGN — the largest reported positions include Dodge & Cox (US$3.04B), DODGE & COX (US$3.04B), Franklin Resources (US$2.75B). Under SEC rules, institutional investment managers with over $100M in assets must file Form 13F within 45 days of each quarter-end, disclosing long positions in US-listed equities. The data excludes short positions, most options and foreign holdings, so treat it as a quarterly snapshot rather than a live position.

Other funds holding REGN

All REGN fund holders →

FAQ

How long has PGGM Investments held REGN?

PGGM Investments has disclosed REGN holdings in 13 of the last 13 reported quarters, going back to Q3 2023.

What is PGGM Investments's current position in REGN?

As of Q3 2026, PGGM Investments holds 25.59K shares of REGN (REGENERON PHARMACEUTICALS), valued at $19.40M, representing 0.48% of its reported portfolio and ranking #50.

Has PGGM Investments been buying or selling REGN?

In the latest 13F filing (Q3 2026), PGGM Investments reduced its position in REGN. The position peaked in Q1 2026 at 92.58K shares.

Which other funds hold REGN?

Other major institutional holders of REGN include Dodge & Cox, DODGE & COX, Franklin Resources, among 29 funds with disclosed positions.

Where does this data come from?

All figures are computed from SEC Form 13F quarterly filings, which institutional investment managers must file within 45 days of quarter end for long positions of $100,000 or more.